Cas9

SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers

Retrieved on: 
Monday, April 1, 2024
Gene editing, Cell, IBN, Partnership, Tissue, Genetics, Medicine, Regenerative medicine, OTC, Cas9, Immune system, Therapy, Vaccine

Genome editing, particularly through the use of CRISPR-Cas9 technology, has emerged as a groundbreaking approach in the field of genetic research and therapeutics.

Key Points: 
  • Genome editing, particularly through the use of CRISPR-Cas9 technology, has emerged as a groundbreaking approach in the field of genetic research and therapeutics.
  • Coastar's red blood cell membrane derived carriers have shown immense potential in efficiently delivering therapeutic cargo into cells.
  • These carriers, derived from the natural membrane of red blood cells, possess several advantages, including biocompatibility, stability, and the ability to evade the immune system.
  • The integration of Coastar's red blood cell membrane derived carriers with SOHM's ABBIE protein-based system holds great promise for both in vitro and in vivo applications.

Arsenal Biosciences Announces Presentation of Four Abstracts at AACR Annual Meeting Highlighting New CAR T-Focused Research

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Ovarian cancer, Short interspersed nuclear element, B cell, Fas, SPA, Glomus tumor, MSLN, Neoplasm, Research, RNA, Tumor microenvironment, Abstract, AACR, CA9, Clinical trial, Cancer, CRISPR, Primer, TCR, Engineering, PSMA, Cas9, ICT, Vaccine

Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.

Key Points: 
  • Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.
  • AB-2100 will be studied in a phase 1/2 clinical trial as a potential therapy for clear cell renal cell carcinoma (ccRCC) ( NCT06245915 ).
  • To better characterize CAR induction and receptor turnover, we conducted a series of assays, ultimately demonstrating preclinically that all PrimeR ICT cells have the potential to induce CAR.
  • Leveraging a reductionist in vitro model system, we were also able to analyze CAR induction and receptor turnover.

Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration

Retrieved on: 
Tuesday, March 26, 2024
Research, Legal, Medical Devices, Patent Law, Genetics, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Trade, CVC, Patent, RNA, CNIPA, Emmanuelle, University, Genomics, CRISPR, Eukaryote, Intellectual property, Cas9

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.
  • The decision to uphold the patent right in China follows a recent decision by the Japanese Patent Office earlier this year to uphold JP6692856, also part of the CVC portfolio1.
  • The decision by the CNIPA, fully upholding the patent, further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: “The decision by the CNIPA is testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio.

Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing

Retrieved on: 
Thursday, March 21, 2024
Other Health, Software, Research, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, AIX, Cas9, OpenAI, Gene editing, Insight Partners, Growth, Spotlight, General partnership, Salesforce, Nature Biotechnology, Gene, Spark Capital, AI, University, Tome, Nature, Protein engineering, Biology, Microbiology, CRISPR, De novo, ChatGPT, Therapy, Machine learning, Probability, Management

Profluent, an AI-first protein design company, today announced the close of additional funding to bring the total raised to $44M.

Key Points: 
  • Profluent, an AI-first protein design company, today announced the close of additional funding to bring the total raised to $44M.
  • “Our research at the forefront of AI has enabled Profluent to create large language models that begin to learn the blueprint of nature,” said Ali Madani, Profluent co-founder and Chief Executive Officer.
  • By first applying its platform to gene editing, the company showcases AI as the ideal interface for engineering complex biological systems.
  • Just as ChatGPT can write compelling essays and emails, Profluent has developed AI that designs entirely new and functional proteins.

Intranasal Delivery of shRNA Edits to Silence 5-HT2A Receptor Shows Promise in Enhancing Memory and Alleviating Anxiety

Retrieved on: 
Thursday, March 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Clinical Trials, Depression, Brain, Dementia, Rat, BBB, Memory, Central nervous system, Public, RNA, Mouse, Traffic barrier, Anxiety, Translational Psychiatry, MCI, Neurological disorder, DSM-IV codes, HTR2A, Intrinsic termination, Therapy, Optimism, Cas9, Vaccine

In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.

Key Points: 
  • In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.
  • Neurological disorders such as Mild Cognitive Impairment (MCI), depression, and anxiety disorders pose significant challenges to public health worldwide.
  • In this study, the researchers designed shRNA sequences to specifically target and silence the human HTR2A gene, which is associated with anxiety and memory.
  • The ability to bypass the blood-brain barrier using intranasal delivery opens up new avenues for precision-based therapeutics in neurological disorders."

Demeetra and Indiana University Biopesticide Platform Combining Gene Editing and Synthetic Biology Selected as a MDPI Journal Editor’s Choice Article

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Health, University, Genetics, Education, MDPI, Generation, Gene editing, Medicine, Saccharomyces cerevisiae, Transposase, Synthetic biology, Sterilization, RNA, Gene, Female, Indiana University, Engineering, Disease, Male, Mosquito control, Plant, Publication, Transgene, SIT, RNA interference, Therapy, Multimedia, Cas9

A pioneering study, authored by scientists from Demeetra and Indiana University, has been selected for the MDPI Journals Editor's Choice Articles , highlighting the impact of advanced gene editing in synthetic biology to produce biopesticides.

Key Points: 
  • A pioneering study, authored by scientists from Demeetra and Indiana University, has been selected for the MDPI Journals Editor's Choice Articles , highlighting the impact of advanced gene editing in synthetic biology to produce biopesticides.
  • View the full release here: https://www.businesswire.com/news/home/20240320823585/en/
    Demeetra and Indiana University research on gene edited yeast biopesticide was featured on the front cover of Fermentation.
  • According to MDPI “Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world.
  • “We wanted to engineer the ideal yeast platform for stable RNAi expression,” said Dr. Corey Brizzee, Director of Gene Editing at Demeetra.

Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement

Retrieved on: 
Wednesday, March 13, 2024
Health, Medical Devices, Health Technology, Genetics, Research, Science, Biotechnology, Chiyoda, Tokyo, Ricoh, B cell, Gene editing, Cell, Drug discovery, Intelligence, Acceleration, Patient, RNA, DNA, Acquisition, Messenger, Sumitomo Corporation, IPS, Regenerative medicine, Multinational corporation, Genomics, CRISPR, Drug development, Cas9, Vaccine

Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.

Key Points: 
  • Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.
  • In 2022, Ricoh completed the acquisition of Elixirgen Scientific, Inc. (Baltimore, Maryland, USA).
  • Ricoh continues to contribute to the acceleration of drug development research through the diverse solutions provided by Elixirgen Scientific.
  • Summit Pharmaceuticals International Corporation (Chiyoda-ku, Tokyo, Japan), a subsidiary of Sumitomo Corporation (Chiyoda-ku, Tokyo, Japan), is the exclusive representative of ERS Genomics in Japan.

BCC Research Reveals Top Ten Suppliers of Synthetic Biology Technology in 2024

Retrieved on: 
Tuesday, April 2, 2024
Research, Automation, Health, Edit, Enzyme, Growth, Commercialization, Top Ten, Agriculture, Drug discovery, Synthetic biology, Livestock, DNA, Health care, Milk, Food safety, Biofuel, Synthetic, CRISPR, Pharma, Therapy, BCC, Vaccine, Cas9, Food industry

BOSTON, April 2, 2024 /PRNewswire/ -- According to the latest BCC Research study, the demand for Top Ten Suppliers of Synthetic Biology Technology is estimated to increase from $35.5 billion in 2023 to $59.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 10.8% during the forecast period of 2023-2028.

Key Points: 
  • With growing interest and investment from countries worldwide, synthetic biology promises sustainable solutions and transformative applications across industries.
  • Furthermore, it provides forecasts for 2028, allowing stakeholders to anticipate future trends and opportunities in the synthetic biology sector.
  • Growth in Synthetic Biology Foundries: Synthetic biology foundries serve as collaborative hubs for research and development, providing access to shared resources, expertise, and standardized biological parts.
  • Increasing Research and Development Investment by Pharma Companies: Pharmaceutical companies are increasingly recognizing the potential of synthetic biology and investing in research and development efforts.

Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats

Retrieved on: 
Monday, March 25, 2024
Research, ESC, Bioreactor, B cell, Regeneration, Neurology, Rat, Cell, Osteogenesis imperfecta, Assistant, Cardiology, Critical Care Medicine (journal), Patient, American Journal, DNA, Pharmacist, Manuscript, Cancer, University, Hope, Doctor of Philosophy, Lung transplantation, MD, Biostatistics, Respiratory failure, Cas9, CRISPR, Stem cell, Premature, Research institute, College of Engineering (KNUST), Medicine, Nursing, Animal

PHOENIX, March 25, 2024 /PRNewswire/ -- Research conducted at the Phoenix Children's Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.

Key Points: 
  • The critical differentiating factor with this study is researchers incorporated CRISPR-Cas9, a unique genome editing technology that allows researchers to change genomes by altering sections of the DNA sequence.
  • Modifications of rat embryos by CRISPR-Cas9 allowed the formation of lung tissues consisting of almost all mouse lung cells.
  • This is one of many recent accolades for the Phoenix Children's Research Institute.
  • The Phoenix Children's Research Institute at the University of Arizona College of Medicine –Phoenix launched in May 2023, formalizing a longstanding research collaboration between the health system and the University of Arizona College of Medicine – Phoenix.

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024
Adolescence, Research, Biotechnology, Gene editing, ASH, FDA, Food, File, TDT, BLA, BCL11A, Safety, Society, Collaboration, Vertex Pharmaceuticals, Patent, Editas Medicine, Patient, Cas9, Sickle cell disease, Public expenditure, Poster, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.
  • In 2023, Editas Medicine strengthened and focused its discovery organization to build an in vivo gene editing pipeline.
  • Editas Medicine plans to participate in the following investor events:
    The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m.
  • ET to provide and discuss a corporate update and financial results for the fourth quarter and full year of 2023.